RxDoctor Payments Data

Zeljka Chobanov, MD

Neurology · Hamilton, OHNPI 1619937158

Payments from drug & device makers

$422in general payments, 2019–2025

Across 15 payments — averaging $28.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$143
  • Amneal Pharmaceuticals LLC$122
  • Biogen$40
  • Livanova USA, Inc.$27
  • EMD Serono, Inc.$26
  • UCB, Inc.$17
  • plus $48 from 3 others

What the payments were for

  • Speaking & faculty fees$12229%
  • Food & beverage$22353%
  • Education$7718%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$422 in reported general payments places this provider in the 35th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$68,526
Medicare patients
312
Services billed
689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe41$43,289
NeuproRotigotine26$21,517
Lacosamide65$6,665
Levetiracetam143$5,189
Memantine Hcl ErMemantine Hcl46$3,899
Memantine Hcl75$3,505
Carbidopa-LevodopaCarbidopa/Levodopa144$3,256
Gabapentin136$2,616
Primidone99$1,775
Clobazam13$1,274
Pregabalin31$836
Ropinirole Hcl34$703
Lamotrigine23$673
Donepezil Hcl100$498
Carbidopa-Levodopa ErCarbidopa/Levodopa31$482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Neupro$17$21,51726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 702 neurology providers in Ohio.

Other neurology in Hamilton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →